Cytokinetics, Inc. (NASDAQ:CYTK) and Origent Data Sciences, Inc. (Origent) announced a research collaboration to refine and prospectively validate an Origent computer model to predict the course of ALS disease progression leveraging data from Cytokinetics’ clinical trials of tirasemtiv. Funded by Origent’s receipt of a grant from The ALS Association, this joint research program will enable the first prospective validation of the predictive model in a clinical trial setting. Previously, the Origent models predicting both function and survival of ALS patients have been validated using internal and retrospective external datasets.

ALS disease progression is extremely heterogeneous among patients.  While the average life expectancy of a patient living with ALS is 3-5 years after diagnosis, many patients survive only a few months, while still others live with the disease for decades. This heterogeneity of progression creates significant challenges for clinical trial design and conduct, as patients who progress at highly variable rates may confound traditional statistical analyses, and require larger, longer and more expensive trials. Origent’s statistical models are designed to identify the patients whose symptoms are likely to progress quickly or slowly, thereby reducing the statistical complexities created by this disease heterogeneity.

“We are extremely grateful to The ALS Association for this generous grant and to Cytokinetics for the opportunity to access their robust clinical trial data,” said Dave Ennist, Chief Science Officer, Origent Data Sciences. “If validated, the models we have developed will be submitted to the FDA and may enable more nimble, cost-effective execution of ALS clinical trials, resulting in a potentially quicker path to new medicines.”

“This unique collaboration between Origent Data Sciences, Cytokinetics and The ALS Associationreflects another step in our collective efforts to accelerate the clinical trial process and make new medicines available to people with ALS in desperate need of new therapeutic options,” said Jinsy Andrews, M.D., Cytokinetics’ Senior Director Clinical Research and Development and Head of Neuromuscular Therapeutics.  “We are pleased to join with Origent to potentially validate their predictive model using datasets from BENEFIT-ALS and VITALITY-ALS which we hope may then facilitate the use of this novel technology to positively impact the design and conduct of future ALS clinical trials.”

“We are extremely excited to see this collaboration get underway,” said ALS Association Chief Scientist Lucie Bruijn, Ph.D., M.B.A. “This tool has the potential to accelerate clinical trials for ALS and the Cytokinetics’ Phase 3 trial provides an excellent opportunity to validate the disease progression algorithm.” (Original Source)

Shares of Cytokinetics closed yesterday at $6.73, down $-0.10 or -1.46%. CYTK has a 1-year high of $13.18 and a 1-year low of $5.50. The stock’s 50-day moving average is $6.56 and its 200-day moving average is $8.47.

On the ratings front, Cytokinetics has been the subject of a number of recent research reports. In a report issued on February 17, Cowen analyst Ritu Baral reiterated a Buy rating on CYTK, with a price target of $16, which represents a potential upside of 137.7% from where the stock is currently trading. Separately, on February 16, Roth Capital’s Joseph Pantginis reiterated a Buy rating on the stock and has a price target of $22.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Ritu Baral and Joseph Pantginis have a total average return of 3.8% and -5.7% respectively. Baral has a success rate of 38.1% and is ranked #708 out of 3775 analysts, while Pantginis has a success rate of 34.5% and is ranked #3705.

Cytokinetics, Inc. is a late-stage biopharmaceutical company, which focuses on the discovery and developments of first-in-class muscle activators as potential treatment for debilitating diseases in which muscle performance is compromised and declining. Its research and development activities relating to the biology of muscle function have evolved from their knowledge and expertise regarding the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.